25.02.2019 23:55:53
|
Press Release: Novartis issues summary financial -2-
potential significant breaches of data security or data privacy, or
disruptions of our information technology systems or those of Alcon as a
standalone company; and other risks and factors referred to in Novartis
AG's current Form 20-F on file with the U.S. Securities and Exchange
Commission (SEC) or in the initial Form 20-F filed by Alcon with the
SEC. Novartis is providing the information in this press release as of
this date and does not undertake any obligation to update any
forward-looking statements as a result of new information, future events
or otherwise.
This press release is not an offer to sell, or a solicitation of an
offer to buy or sell, any securities of Novartis or, following the
proposed spinoff, of Alcon, and may not be relied upon in connection
with the purchase or sale of any such security. Should you wish to
invest in Alcon, you should do so solely on the basis of information
Alcon will file with the SEC at or around the time of the spinoff,
including the section "Risk Factors" included in the Form 20-F. The
information filed with the SEC will be available on the SEC's website at
www.sec.gov.
About Novartis
Novartis is reimagining medicine to improve and extend people's lives.
As a leading global medicines company, we use innovative science and
digital technologies to create transformative treatments in areas of
great medical need. In our quest to find new medicines, we consistently
rank among the world's top companies investing in research and
development. Novartis products reach more than 800 million people
globally and we are finding innovative ways to expand access to our
latest treatments. About 130,000 people of more than 145 nationalities
work at Novartis around the world. To learn more, visit
www.novartis.com.
About Alcon
Alcon is the global leader in eye care devices. As a division of
Novartis, we offer the broadest portfolio of products to enhance sight
and improve people's lives. Our products touch the lives of more than
260 million people each year living with conditions like cataracts,
glaucoma, retinal diseases and refractive errors, and there are millions
more who are waiting for solutions to meet their eye care needs. Our
purpose is reimagining eye care, and we do this through innovative
products, partnerships with eye care professionals and programs that
enhance access to quality eye care. Learn more at www.alcon.com (link is
external).
Novartis is on Twitter. Sign up to follow @Novartis at
http://twitter.com/novartis
For Novartis multimedia content, please visit
www.novartis.com/news/media-library
For questions about the site or required registration, please contact
media.relations@novartis.com
# # #
Novartis Media Relations
Central media line: +41 61 324 2200
E-mail: media.relations@novartis.com
Paul Barrett Wes Warnock
Novartis Group Communications Alcon Global External Communications
+41 61 324 5224 (direct) +1 817 615 2501 (direct)
+41 79 797 8137 (mobile) +1 210 240 4998 (mobile)
paul.barett@novartis.com wes.warnock@alcon.com
Eric Althoff
Novartis Global Media Relations
+41 61 324 7999 (direct)
+41 79 593 4202 (mobile)
eric.althoff@novartis.com
Novartis Investor Relations
Central investor relations line: +41 61 324 7944
E-mail: investor.relations@novartis.com
Central North America
Samir Shah +41 61 324 7944 Richard Pulik +1 212 830 2448
Pierre-Michel Bringer +41 61 324 1065 Cory Twining +1 212 830 2417
Thomas Hungerbuehler +41 61 324 8425
Isabella Zinck +41 61 324 7188
Media release (PDF): http://hugin.info/134323/R/2236409/880733.pdf
This announcement is distributed by West Corporation on behalf of West
Corporation clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the information
contained therein.
Source: Novartis International AG via Globenewswire
--- End of Message ---
Novartis International AG
P.O. Box Basel Switzerland
WKN: 904278;ISIN: CH0012005267;
http://www.novartis.com
(END) Dow Jones Newswires
February 25, 2019 17:55 ET (22:55 GMT)
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Novartis AGmehr Nachrichten
25.11.24 |
STOXX 50 aktuell: STOXX 50 schlussendlich mit Abgaben (finanzen.at) | |
25.11.24 |
Schwache Performance in Zürich: SLI schwächelt letztendlich (finanzen.at) | |
25.11.24 |
Börse Zürich in Rot: SMI verbucht zum Handelsende Verluste (finanzen.at) | |
25.11.24 |
Gute Stimmung in Europa: STOXX 50 am Montagnachmittag freundlich (finanzen.at) | |
25.11.24 |
Freundlicher Handel: SLI am Nachmittag mit Zuschlägen (finanzen.at) | |
25.11.24 |
Schwacher Wochentag in Zürich: SMI am Nachmittag schwächer (finanzen.at) | |
25.11.24 |
Handel in Zürich: SLI am Montagmittag mit positivem Vorzeichen (finanzen.at) | |
25.11.24 |
Börse Zürich: So steht der SMI aktuell (finanzen.at) |
Analysen zu Novartis AGmehr Analysen
25.11.24 | Novartis Hold | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | |
22.11.24 | Novartis Hold | Deutsche Bank AG | |
22.11.24 | Novartis Neutral | Goldman Sachs Group Inc. | |
21.11.24 | Novartis Neutral | Goldman Sachs Group Inc. | |
21.11.24 | Novartis Underweight | Barclays Capital |